Nuwellis announces first pediatric patient treated in a commercial setting with seastar medical's quelimmune™ therapy at cincinnati children's

Minneapolis, july 26, 2024 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that the first patient has been treated with the newly launched quelimmune™ therapy in a commercial setting at cincinnati children's. quelimmune, manufactured for seastar medical (nasdaq: icu) and exclusively licensed and distributed in u.s. pediatric hospitals by nuwellis, is a novel therapy designed to treat pediatric patients (weighing 10 kg or more) suffering from acute kidney injury (aki) with sepsis or a septic condition and requiring kidney replacement therapy (krt).
NUWE Ratings Summary
NUWE Quant Ranking